In the Phase II portion of HUTCHMED’s randomized Phase II/III study in first-line metastatic pancreatic ductal adenocarcinoma (PDAC), the surufatinib + camrelizumab + nab-paclitaxel + gemcitabine regimen delivered a median progression-free survival of 7.20 months versus 5.52 months on nab-paclitaxel/gemcitabine alone (HR 0.499; p=0.0407). Objective response rate was 67.7% versus 41.9% (p=0.0430) and disease control rate was 93.5% versus 71.0% (p=0.0149). Overall survival was immature but trended favorably (not reached vs 8.48 months; HR 0.555) with 9 versus 15 events in equally sized arms (N=31 each). Grade ≥3 treatment-emergent adverse events occurred in 80.6% of patients on the quadruplet versus 61.3% on control.

The company has now opened the Phase III segment in China, dosing the first patient on December 30, 2025. The multicenter, randomized, open-label, active-controlled trial will add approximately 400 participants to compare the quadruplet against nab-paclitaxel/gemcitabine, with overall survival as the primary endpoint and PFS, ORR, DoR, DCR, quality of life, and safety as secondary measures. The design keeps eligibility broad—no biomarker gating—and uses a China-standard control, positioning the study for a potential NMPA filing if the survival signal holds.

Strategically, HUTCHMED is leaning into an angio–immuno–chemotherapy construct to tackle PDAC’s hostile microenvironment, pairing a VEGFR/FGFR/CSF1R inhibitor (surufatinib) with a PD-1 antibody (camrelizumab) on top of established chemotherapy. The Phase II signal is directionally encouraging in a setting where immunotherapy has rarely moved the needle outside of MSI-H niches. The choice of OS as the pivotal endpoint aligns with regulatory expectations and avoids over-reliance on PFS in a disease prone to symptomatic progression and imaging ambiguity. The trade-off is complexity and toxicity: a four-drug regimen delivered higher grade ≥3 AE rates in Phase II, raising the bar for dose intensity, adherence, and real-world tolerability if the efficacy delta is modest.

For sites, this is an operationally heavy protocol. Weekly chemotherapy infusions layered with PD-1 administration and daily oral surufatinib increases chair time, AE monitoring, and coordination across oncology, infusion, and pharmacy teams. Immune-related toxicity management on top of cytotoxic adverse events will test staffing and protocol training, particularly in high-volume centers managing biliary drainage, thromboembolic risk, and rapid clinical deterioration common in PDAC. For CROs and sponsors, drug supply and accountability across four agents—spanning an oral TKI, a biologic from a partner company, and two chemotherapies—adds logistical risk and SAE reporting burden. The biomarker-agnostic design simplifies screening and should support fast enrollment in China, but it may limit mechanistic read-throughs that global regulators increasingly expect to contextualize benefit.

If Phase III confirms an OS benefit with a manageable safety profile, HUTCHMED could pursue a first-line PDAC label in China, challenging nab-paclitaxel/gemcitabine alone and potentially displacing use in patients unsuitable for FOLFIRINOX. However, external generalizability and competitive positioning will be scrutinized, given the absence of an oxaliplatin-based comparator and the regimen’s AE profile. Global expansion is an open question: surufatinib remains China-marketed, and camrelizumab is China-only, which complicates multinational development and commercialization pathways without alternative pairings and additional MRCT evidence.

Key watch items include timing and stringency of interim OS analyses, dose intensity and discontinuation trends in the larger cohort, and whether the PFS and ORR advantages translate into durable survival. Site performance metrics—screen fail rates, early drop-outs, and immune-related AE management—will be leading indicators of whether this quadruplet can scale beyond controlled trial settings.

Source link: https://www.globenewswire.com/news-release/2026/01/05/3212410/0/en/HUTCHMED-Initiates-Phase-III-Stage-of-the-Ongoing-Trial-of-the-Combination-of-Surufatinib-and-Camrelizumab-for-Treatment-Na%C3%AFve-Pancreatic-Ductal-Adenocarcinoma.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.